PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary ...

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...

WorldTrips, based in Carmel, Indiana, a leading provider of global travel medical insurance, is excited to announce the launch of its latest travel medical product, Atlas JapanSecure. This new ...

The U.S. Food and Drug Administration has announced its approval of BridgeBio's innovative drug, Attruby, aimed at treating ...

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by BridgeBio for the distribution of Attrubytm ...

On Nov. 18, the heart failure and transplantation team at Emory University Hospital (EUH) made history, performing the first-ever surgical implantation in the United States of a brand-new type of ...

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing ...

Lockheed Martin has felt financial strain as early funding for the upcoming F-35 jets dried up, but kept working on them to avoid supply chain disruptions.